stoxline Quote Chart Rank Option Currency Glossary
  
Lineage Cell Therapeutics, Inc. (LCTX)
0.6987  0.094 (15.58%)    05-23 16:00
Open: 0.6
High: 0.7
Volume: 2,376,327
  
Pre. Close: 0.6045
Low: 0.6
Market Cap: 160(M)
Technical analysis
2025-05-23 4:49:11 PM
Short term     
Mid term     
Targets 6-month :  0.81 1-year :  0.95
Resists First :  0.69 Second :  0.81
Pivot price 0.49
Supports First :  0.51 Second :  0.4
MAs MA(5) :  0.55 MA(20) :  0.49
MA(100) :  0.53 MA(250) :  0.72
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  97.7 D(3) :  89.6
RSI RSI(14): 76.1
52-week High :  1.14 Low :  0.37
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ LCTX ] has closed above the upper band by 26.3%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 90.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.7 - 0.7 0.7 - 0.71
Low: 0.59 - 0.6 0.6 - 0.6
Close: 0.69 - 0.7 0.7 - 0.7
Company Description

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Headline News

Wed, 21 May 2025
Transcript : Lineage Cell Therapeutics, Inc. Presents at H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025, May-20-2025 02 - marketscreener.com

Thu, 15 May 2025
Lineage Cell Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks

Wed, 14 May 2025
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2025 Earnings Call Transcript - Insider Monkey

Wed, 14 May 2025
Lineage Cell Therapeutics Inc (LCTX) Q1 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Tue, 13 May 2025
Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance

Thu, 01 May 2025
Lineage Cell Therapeutics announces cGMP production success - Investing.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
AMEX
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 189 (M)
Shares Float 146 (M)
Held by Insiders 0.4 (%)
Held by Institutions 50.3 (%)
Shares Short 15,820 (K)
Shares Short P.Month 14,560 (K)
Stock Financials
EPS -0.13
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.36
Profit Margin 0 %
Operating Margin -416.7 %
Return on Assets (ttm) -12.9 %
Return on Equity (ttm) -35.1 %
Qtrly Rev. Growth -56.3 %
Gross Profit (p.s.) 0
Sales Per Share 0.03
EBITDA (p.s.) -0.12
Qtrly Earnings Growth 0 %
Operating Cash Flow -22 (M)
Levered Free Cash Flow -9 (M)
Stock Valuations
PE Ratio -5.38
PEG Ratio 0
Price to Book value 1.94
Price to Sales 21.31
Price to Cash Flow -6
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android